Erratum to: Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology [Diabetes Therapy, (2014), 5, 2, 355-366, 10.1007/s13300-014-0089-4];Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

Diabetes Therapy

Volumn 5, Issue 2, 2014, Pages 355-366

  Kalra, Sanjay ^a  

^a Bharti Hospital and BRIDE ^*  (India)

Author keywords

Anti diabetic drugs; Canagliflozin; Cardiovascular safety; Dapagliflozin; Empagliflozin; Perineal hygiene; Sodium glucose co transporter 2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DAPAGLIFLOZIN PLUS METFORMIN; DIURETIC AGENT; EMPAGLIFLOZIN; GLIMEPIRIDE PLUS METFORMIN; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN;

CARDIOVASCULAR RISK; CLINICAL PHARMACOLOGY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG DOSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); OSMOTIC DIURESIS; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT INFECTION; WEIGHT REDUCTION;

EID: 84919662775     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0095-1     Document Type: Erratum

References (44)

1. Abdul GM, DeFronzo R. Dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2013;14:1695–703.
2. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63–71.
3. Ehrenkranz J, Lewis N, Ronald KC, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–8.
4. Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1):F10–8.
5. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007;(106):S27–35.
6. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal NA+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011;300:C721.
7. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–80.
8. Mudaliar S, Henry R, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16:137–44.
9. Kasichayanula S, Liu X, LaCreta F, Griffen S, Boulton D. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53:17–27.
10. Canagliflozin prescribing information, Janssen Pharmaceuticals. 2014. https://www.invokanahcp.com/prescribing-information.pdf.
11. Zhang L, Feng Y, List J, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510–6.
12. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.
13. Rohwedder K, Johnsson E, Parikh S. Reduced risk of hypoglycemic events with dapagliflozin vs. glipizide as add-on therapy in type 2 diabetes mellitus: 4-year data from a phase 3 study. In: Poster presented at 50th Annual meeting of the European Association for the Study of Diabetes. Vienna; 2014.
14. Rosenstock J, Jelaska A, Wang F, et al. Empagliflozin as add- on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Can J Diabetes. 2013;37:S32.
15. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–14.
16. Scheen A. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–25.
17. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74.
18. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–62.
19. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. In: Abstract 942 presented at the 49th European Association for the Study of Diabetes Annual Meeting, September 23–27, Barcelona, Spain. Diabetologia 2013;56:S377.
20. Weir MR, Januszewicz A, Gilbert RE, Lavalle Gonzalez FJ, Meininger G. Lower blood pressure (BP) with canagliflozin (cana) in subjects with type 2 diabetes mellitus (T2DM). Diabetes. 2013;62(Suppl 1):Abstract 1077-P.
21. Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study diabetes care. 2014. (pii: DC_132762). [Epub ahead of print].
22. Sha S, Devineni D, Ghosh A, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014;9:e105638.
23. Hach T, Gerich J, Salsali A et al. Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetologia 2013;56(Suppl 1):S377 (Abstract 943).
24. Del Prato S, Nauck MA, Durán-Garcia S, et al. Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data [Abstract]. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0687e7c8-c97d-442b-92ec-ae505e051854&cKey=9bb1b5dd-fbfe-4de6-9b27-054820e39f63&mKey={89918D6D-3018-4EA9-9D4F-711F98A7AE5D}. Accessed 14 Nov 2014.
25. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37:815–29.
26. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS): a randomized placebo-controlled trial. Am Heart J. 2013;166:217–223 e11.
27. Bolinder J, Ljunggren, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–69.
28. Ruggenenti P, Porrini Esteban L, Gaspari F, Motterlini N, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061–8.
29. Dapagliflozin prescribing information, AstraZeneca Pharmaceuticals. 2014.
30. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Invest. 2014;5:265–75.
31. Rossenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453–67.
32. Sarnoski-Brokavich S, Hilas O. Canagliflozin (invokana), a novel oral agent for type-2 diabetes. P T. 2013;38:665–6.
33. Johnsson Kristina M, Ptaszynska Agata, Schmitz Bridget, Sugg Jennifer, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27:479–84.
34. Kalra S, Baruah MP, Sahay R. Medication counselling with sodium glucose transporter 2 inhibitor therapy. Indian J Endocrinol Metab. 2014;18:597–9.
35. Stenlof K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30:163–75.
36. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015–21.
37. Empagliflozin. www.clinicaltrials.gov. U.S. National Institutes of Health. Retrieved May 8, 2014.
38. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–15.
39. Ptaszynska A, Mansfield T, Johnsson E, Parikh SJ, Yavin Y, List JF. Long-term renal Safety with dapagliflozin treatment. In: Poster presented at 50th Annual meeting of the European Association for the Study of Diabetes. Vienna; 2014.
40. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2014. (pii:DC_132955) [Epub ahead of print].
41. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97.
42. Cherney DZ, Perkins BA. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection. Can J Diabetes. 2014;38:356–63.
43. Nagata T, Fukazawa M, Honda K, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013;304:414–23.
44. Ohtake Y, Sato T, Kobayashi T, et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012;55:7828–40.